Tumor-associated macrophages in thoracic malignancies

Lung Cancer

Volumn 80, Issue 3, 2013, Pages 256-262

  Lievense, L A ^a   Bezemer, K ^a   Aerts, J G J V ^a,b   Hegmans, J P J J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b AMPHIA HOSPITAL   (Netherlands)

Author keywords

Immuno oncology; Immunotherapy; Lung cancer; Mesothelioma; Personalized medicine; Tumor microenvironment

Indexed keywords

ASBESTOS FIBER; CD163 ANTIGEN; CLODRONIC ACID; GAMMA INTERFERON; GELATINASE B; GLYCERYL TRINITRATE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYPOXIA INDUCIBLE FACTOR; I KAPPA B KINASE BETA; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MACROPHAGE DERIVED CHEMOKINE; MANNOSE RECEPTOR; MONOCYTE CHEMOTACTIC PROTEIN 1; PLACENTAL GROWTH FACTOR; PROSTAGLANDIN E2; SILTUXIMAB; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TIRAPAZAMINE; TOLL LIKE RECEPTOR 7; VASCULOTROPIN; ZOLEDRONIC ACID;

ADAPTIVE IMMUNITY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; CELL SURVIVAL; CHEMORADIOTHERAPY; CYTOKINE PRODUCTION; HUMAN; IMMUNOCOMPETENT CELL; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LYMPH NODE METASTASIS; MALIGNANT MESOTHELIOMA; NONHUMAN; OUTCOME ASSESSMENT; PATHOGENESIS; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; THORAX CANCER; TUMOR ASSOCIATED LEUKOCYTE; TUMOR BLOOD FLOW; TUMOR MICROENVIRONMENT;

CARCINOGENESIS; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MACROPHAGES; MESOTHELIOMA; PROGNOSIS; TUMOR MICROENVIRONMENT;

EID: 84877126027     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.02.017     Document Type: Review

References (104)

1. Talmadge J.E., Donkor M., Scholar E. Inflammatory cell infiltration of tumors: Jekyll or Hyde. Cancer Metastasis Rev 2007, 26(3-4):373-400.
2. Shankaran V., Ikeda H., Bruce A.T., White J.M., Swanson P.E., Old L.J., et al. IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature 2001, 410(6832):1107-1111.
3. Dunn G.P., Old L.J., Schreiber R.D. The three Es of cancer immunoediting. Annu Rev Immunol 2004, 22:329-360.
4. Schreiber R.D., Old L.J., Smyth M.J. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011, 331(6024):1565-1570.
5. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer 2005, 5(4):263-274.
6. Woo E.Y., Yeh H., Chu C.S., Schlienger K., Carroll R.G., Riley J.L., et al. Regulatory T cells from lung cancer patients directly inhibit autologous T cell proliferation. J Immunol 2002, 168(9):4272-4276. Cutting edge:.
7. Batra R.K., Lin Y., Sharma S., Dohadwala M., Luo J., Pold M., et al. Non-small cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymphocytes through an I kappa B kinase-dependent mechanism. Cancer Res 2003, 63(3):642-646.
8. DeLong P., Carroll R.G., Henry A.C., Tanaka T., Ahmad S., Leibowitz M.S., et al. Regulatory T cells and cytokines in malignant pleural effusions secondary to mesothelioma and carcinoma. Cancer Biol Ther 2005, 4(3):342-346.
9. Hegmans J.P., Hemmes A., Hammad H., Boon L., Hoogsteden H.C., Lambrecht B.N. Mesothelioma environment comprises cytokines and T-regulatory cells that suppress immune responses. Eur Respir J 2006, 27(6):1086-1095.
10. Meloni F., Morosini M., Solari N., Passadore I., Nascimbene C., Novo M., et al. Foxp3 expressing CD4+CD25+ and CD8+CD28- T regulatory cells in the peripheral blood of patients with lung cancer and pleural mesothelioma. Hum Immunol 2006, 67(1-2):1-12.
11. Cornelissen R., Lievense L.A., Heuvers M.E., Maat A.P., Hendriks R.W., Hoogsteden H.C., et al. Dendritic cell-based immunotherapy in mesothelioma. Immunotherapy 2012, 4(10):1011-1022.
12. Thomas A., Hassan R. Immunotherapies for non-small-cell lung cancer and mesothelioma. Lancet Oncol 2012, 13(7):e301-e310.
13. Hegmans J.P., Veltman J.D., Lambers M.E., de Vries I.J., Figdor C.G., Hendriks R.W., et al. Consolidative dendritic cell-based immunotherapy elicits cytotoxicity against malignant mesothelioma. Am J Respir Crit Care Med 2010, 181(12):1383-1390.
14. Cornelissen R., Heuvers M.E., Maat A.P., Hendriks R.W., Hoogsteden H.C., Aerts J.G., et al. New roads open up for implementing immunotherapy in mesothelioma. Clin Dev Immunol 2012, 927240.
15. Bronte V., Serafini P., Apolloni E., Zanovello P. Tumor-induced immune dysfunctions caused by myeloid suppressor cells. J Immunother 2001, 24(6):431-446.
16. Sakaguchi S., Yamaguchi T., Nomura T., Ono M. Regulatory T cells and immune tolerance. Cell 2008, 133(5):775-787.
17. Sica A., Allavena P., Mantovani A. Cancer related inflammation: the macrophage connection. Cancer Lett 2008, 267(2):204-215.
18. Allavena P., Sica A., Garlanda C., Mantovani A. The Yin-Yang of tumor-associated macrophages in neoplastic progression and immune surveillance. Immunol Rev 2008, 222:155-161.
19. Yamaguchi T., Sakaguchi S. Regulatory T cells in immune surveillance and treatment of cancer. Semin Cancer Biol 2006, 16(2):115-123.
20. Balkwill F., Mantovani A. Inflammation and cancer: back to Virchow?. Lancet 2001, 357(9255):539-545.
21. Pollard J.W. Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 2004, 4(1):71-78.
22. Pollard J.W. Trophic macrophages in development and disease. Nat Rev Immunol 2009, 9(4):259-270.
23. Ohno S., Ohno Y., Suzuki N., Kamei T., Koike K., Inagawa H., et al. Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res 2004, 24(5C):3335-3342.
24. Takanami I., Takeuchi K., Kodaira S. Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology 1999, 57(2):138-142.
25. Leek R.D., Lewis C.E., Whitehouse R., Greenall M., Clarke J., Harris A.L. Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res 1996, 56(20):4625-4629.
26. Lissbrant I.F., Stattin P., Wikstrom P., Damber J.E., Egevad L., Bergh A. Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival. Int J Oncol 2000, 17(3):445-451.
27. Hanada T., Nakagawa M., Emoto A., Nomura T., Nasu N., Nomura Y. Prognostic value of tumor-associated macrophage count in human bladder cancer. Int J Urol 2000, 7(7):263-269.
28. Srivastava M.K., Andersson A., Zhu L., Harris-White M., Lee J.M., Dubinett S., et al. Myeloid suppressor cells and immune modulation in lung cancer. Immunotherapy 2012, 4(3):291-304.
29. Sica A., Mantovani A. Macrophage plasticity and polarization: in vivo veritas. J Clin Invest 2012, 122(3):787-795.
30. Heusinkveld M., van der Burg S.H. Identification and manipulation of tumor associated macrophages in human cancers. J Transl Med 2011, 9:216.
31. Brower V. Macrophages: cancer therapy's double-edged sword. J Natl Cancer Inst 2012, 104(9):649-652.
32. Solinas G., Germano G., Mantovani A., Allavena P. Tumor-associated macrophages (TAM) as major players of the cancer-related inflammation. J Leukoc Biol 2009, 86(5):1065-1073.
33. Martinez F.O., Helming L., Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009, 27:451-483.
34. Martinez F.O., Sica A., Mantovani A., Locati M. Macrophage activation and polarization. Front Biosci 2008, 13:453-461.
35. Biswas S.K., Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol 2010, 11(10):889-896.
36. Chen C., Shen Y., Qu Q.X., Chen X.Q., Zhang X.G., Huang J.A. Induced expression of B7-H3 on the lung cancer cells and macrophages suppresses T-cell mediating anti-tumor immune response. Exp Cell Res 2013, 319(1):96-102.
37. Schmid M.C., Varner J.A. Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation. J Oncol 2010, 201026.
38. Bremnes R.M., Al-Shibli K., Donnem T., Sirera R., Al-Saad S., Andersen S., et al. The role of tumor-infiltrating immune cells and chronic inflammation at the tumor site on cancer development, progression, and prognosis: emphasis on non-small cell lung cancer. J Thorac Oncol 2011, 6(4):824-833.
39. Ruffell B., Affara N.I., Coussens L.M. Differential macrophage programming in the tumor microenvironment. Trends Immunol 2012, 33(3):119-126.
40. Lewis C., Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol 2005, 167(3):627-635.
41. Escribese M.M., Casas M., Corbi A.L. Influence of low oxygen tensions on macrophage polarization. Immunobiology 2012, 217(12):1233-1240.
42. Lewis C.E., Hughes R. Inflammation and breast cancer. Microenvironmental factors regulating macrophage function in breast tumours: hypoxia and angiopoietin-2. Breast Cancer Res 2007, 9(3):209.
43. White J.R., Harris R.A., Lee S.R., Craigon M.H., Binley K., Price T., et al. Genetic amplification of the transcriptional response to hypoxia as a novel means of identifying regulators of angiogenesis. Genomics 2004, 83(1):1-8.
44. Ran S., Montgomery K.E. Macrophage-mediated lymphangiogenesis: the emerging role of macrophages as lymphatic endothelial progenitors. Cancers (Basel) 2012, 4(3):618-657.
45. Schoppmann S.F., Birner P., Stockl J., Kalt R., Ullrich R., Caucig C., et al. Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis. Am J Pathol 2002, 161(3):947-956.
46. Zhang B.C., Gao J., Wang J., Rao Z.G., Wang B.C., Gao J.F. Tumor-associated macrophages infiltration is associated with peritumoral lymphangiogenesis and poor prognosis in lung adenocarcinoma. Med Oncol 2011, 28(4):1447-1452.
47. Storr S.J., Safuan S., Mitra A., Elliott F., Walker C., Vasko M.J., et al. Objective assessment of blood and lymphatic vessel invasion and association with macrophage infiltration in cutaneous melanoma. Mod Pathol 2012, 25(4):493-504.
48. Biswas S.K., Sica A., Lewis C.E. Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms. J Immunol 2008, 180(4):2011-2017.
49. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., et al. Cancer statistics, 2005. CA Cancer J Clin 2005, 55(1):10-30.
50. Detterbeck F.C., Boffa D.J., Tanoue L.T. The new lung cancer staging system. Chest 2009, 136(1):260-271.
51. Kelsall M.A. Relationships of lymphocytes and cancer. Science 1945, 102(2653):456-457.
52. Kinchner H. Macrophages against cancer. Lancet 1976, 2(7994):1092.
53. Welsh T.J., Green R.H., Richardson D., Waller D.A., O'Byrne K.J., Bradding P. Macrophage and mast-cell invasion of tumor cell islets confers a marked survival advantage in non-small-cell lung cancer. J Clin Oncol 2005, 23(35):8959-8967.
54. Dai F., Liu L., Che G., Yu N., Pu Q., Zhang S., et al. The number and microlocalization of tumor-associated immune cells are associated with patient's survival time in non-small cell lung cancer. BMC Cancer 2010, 10:220.
55. Ohri C.M., Shikotra A., Green R.H., Waller D.A., Bradding P. Macrophages within NSCLC tumour islets are predominantly of a cytotoxic M1 phenotype associated with extended survival. Eur Respir J 2009, 33(1):118-126.
56. Ma J., Liu L., Che G., Yu N., Dai F., You Z. The M1 form of tumor-associated macrophages in non-small cell lung cancer is positively associated with survival time. BMC Cancer 2010, 10:112.
57. Chung F.T., Lee K.Y., Wang C.W., Heh C.C., Chan Y.F., Chen H.W., et al. Tumor-associated macrophages correlate with response to epidermal growth factor receptor-tyrosine kinase inhibitors in advanced non-small cell lung cancer. Int J Cancer 2012, 131(3):E227-E235.
58. Ohtaki Y., Ishii G., Nagai K., Ashimine S., Kuwata T., Hishida T., et al. Stromal macrophage expressing CD204 is associated with tumor aggressiveness in lung adenocarcinoma. J Thorac Oncol 2010, 5(10):1507-1515.
59. Zhang B., Yao G., Zhang Y., Gao J., Yang B., Rao Z. M2-polarized tumor-associated macrophages are associated with poor prognoses resulting from accelerated lymphangiogenesis in lung adenocarcinoma. Clinics (Sao Paulo) 2011, 66(11):1879-1886.
60. Zeni E., Mazzetti L., Miotto D., Lo Cascio N., Maestrelli P., Querzoli P., et al. Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer. Eur Respir J 2007, 30(4):627-632.
61. Wang R., Lu M., Zhang J., Chen S., Luo X., Qin Y., et al. Increased IL-10 mRNA expression in tumor-associated macrophage correlated with late stage of lung cancer. J Exp Clin Cancer Res 2011, 30:62.
62. Hatanaka H., Abe Y., Kamiya T., Morino F., Nagata J., Tokunaga T., et al. Clinical implications of interleukin (IL)-10 induced by non-small-cell lung cancer. Ann Oncol 2000, 11(7):815-819.
63. Wang R., Zhang J., Chen S., Lu M., Luo X., Yao S., et al. Tumor-associated macrophages provide a suitable microenvironment for non-small lung cancer invasion and progression. Lung Cancer 2011, 74(2):188-196.
64. Vallieres E., Shepherd F.A., Crowley J., Van Houtte P., Postmus P.E., Carney D., et al. The IASLC Lung Cancer Staging Project: proposals regarding the relevance of TNM in the pathologic staging of small cell lung cancer in the forthcoming (seventh) edition of the TNM classification for lung cancer. J Thorac Oncol 2009, 4(9):1049-1059.
65. Vogelzang N.J., Rusthoven J.J., Symanowski J., Denham C., Kaukel E., Ruffie P., et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003, 21(14):2636-2644.
66. Robinson B.W., Musk A.W., Lake R.A. Malignant mesothelioma. Lancet 2005, 366(9483):397-408.
67. Bograd A.J., Suzuki K., Vertes E., Colovos C., Morales E.A., Sadelain M., et al. Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. Cancer Immunol Immunother 2011, 60(11):1509-1527.
68. Izzi V., Masuelli L., Tresoldi I., Foti C., Modesti A., Bei R. Immunity and malignant mesothelioma: from mesothelial cell damage to tumor development and immune response-based therapies. Cancer Lett 2012, 322(1):18-34.
69. Leigh R.A., Webster I. Lymphocytic infiltration of pleural mesothelioma and its significance for survival. S Afr Med J 1982, 61(26):1007-1009.
70. Demetri G.D., Zenzie B.W., Rheinwald J.G., Griffin J.D. Expression of colony-stimulating factor genes by normal human mesothelial cells and human malignant mesothelioma cells lines in vitro. Blood 1989, 74(3):940-946.
71. Schmitter D., Lauber B., Fagg B., Stahel R.A. Hematopoietic growth factors secreted by seven human pleural mesothelioma cell lines: interleukin-6 production as a common feature. Int J Cancer 1992, 51(2):296-301.
72. Izzi V., Chiurchiu V., D'Aquilio F., Palumbo C., Tresoldi I., Modesti A., et al. Differential effects of malignant mesothelioma cells on THP-1 monocytes and macrophages. Int J Oncol 2009, 34(2):543-550.
73. Sharma S., Yang S.C., Zhu L., Reckamp K., Gardner B., Baratelli F., et al. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+CD25+ T regulatory cell activities in lung cancer. Cancer Res 2005, 65(12):5211-5220.
74. Baratelli F., Lin Y., Zhu L., Yang S.C., Heuze-Vourc'h N., Zeng G., et al. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells. J Immunol 2005, 175(3):1483-1490.
75. Veltman J.D., Lambers M.E., van Nimwegen M., Hendriks R.W., Hoogsteden H.C., Hegmans J.P., et al. Zoledronic acid impairs myeloid differentiation to tumour-associated macrophages in mesothelioma. Br J Cancer 2010, 103(5):629-641.
76. Miselis N.R., Wu Z.J., Van Rooijen N., Kane A.B. Targeting tumor-associated macrophages in an orthotopic murine model of diffuse malignant mesothelioma. Mol Cancer Ther 2008, 7(4):788-799.
77. Burt B.M., Rodig S.J., Tilleman T.R., Elbardissi A.W., Bueno R., Sugarbaker D.J. Circulating and tumor-infiltrating myeloid cells predict survival in human pleural mesothelioma. Cancer 2011, 117(22):5234-5244.
78. Nakanishi Y., Nakatsuji M., Seno H., Ishizu S., Akitake-Kawano R., Kanda K., et al. COX-2 inhibition alters the phenotype of tumor-associated macrophages from M2 to M1 in ApcMin/+ mouse polyps. Carcinogenesis 2011, 32(9):1333-1339.
79. Fridlender Z.G., Buchlis G., Kapoor V., Cheng G., Sun J., Singhal S., et al. CCL2 blockade augments cancer immunotherapy. Cancer Res 2010, 70(1):109-118.
80. Byrne S.N., Knox M.C., Halliday G.M. TGFbeta is responsible for skin tumour infiltration by macrophages enabling the tumours to escape immune destruction. Immunol Cell Biol 2008, 86(1):92-97.
81. Coward J., Kulbe H., Chakravarty P., Leader D., Vassileva V., Leinster D.A., et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011, 17(18):6083-6096.
82. DeNardo D.G., Brennan D.J., Rexhepaj E., Ruffell B., Shiao S.L., Madden S.F., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov 2011, 1(1):54-67.
83. Hume D.A., MacDonald K.P. Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood 2012, 119(8):1810-1820.
84. Luo Y., Zhou H., Krueger J., Kaplan C., Lee S.H., Dolman C., et al. Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 2006, 116(8):2132-2141.
85. Lewen S., Zhou H., Hu H.D., Cheng T., Markowitz D., Reisfeld R.A., et al. A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol Immunother 2008, 57(4):507-515.
86. Fong C.H., Bebien M., Didierlaurent A., Nebauer R., Hussell T., Broide D., et al. An antiinflammatory role for IKKbeta through the inhibition of " classical" macrophage activation. J Exp Med 2008, 205(6):1269-1276.
87. Hagemann T., Lawrence T., McNeish I., Charles K.A., Kulbe H., Thompson R.G., et al. Re-educating" tumor-associated macrophages by targeting NF-kappaB. J Exp Med 2008, 205(6):1261-1268.
88. Buhtoiarov I.N., Sondel P.M., Wigginton J.M., Buhtoiarova T.N., Yanke E.M., Mahvi D.A., et al. Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology 2011, 132(2):226-239.
89. Chuang C.M., Monie A., Hung C.F., Wu T.C. Treatment with imiquimod enhances antitumor immunity induced by therapeutic HPV DNA vaccination. J Biomed Sci 2010, 17:32.
90. Rogers T.L., Holen I. Tumour macrophages as potential targets of bisphosphonates. J Transl Med 2011, 9:177.
91. U'Ren L., Guth A., Kamstock D., Dow S. Type I interferons inhibit the generation of tumor-associated macrophages. Cancer Immunol Immunother 2010, 59(4):587-598.
92. von Marschall Z., Scholz A., Cramer T., Schafer G., Schirner M., Oberg K., et al. Effects of interferon alpha on vascular endothelial growth factor gene transcription and tumor angiogenesis. J Natl Cancer Inst 2003, 95(6):437-448.
93. Stark G.R., Kerr I.M., Williams B.R., Silverman R.H., Schreiber R.D. How cells respond to interferons. Annu Rev Biochem 1998, 67:227-264.
94. Huang Y., Snuderl M., Jain R.K. Polarization of tumor-associated macrophages: a novel strategy for vascular normalization and antitumor immunity. Cancer Cell 2011, 19(1):1-2.
95. Jain R.K. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7(9):987-989.
96. Mantovani A., Sica A. Macrophages, innate immunity and cancer: balance, tolerance, and diversity. Curr Opin Immunol 2010, 22(2):231-237.
97. Rolny C., Mazzone M., Tugues S., Laoui D., Johansson I., Coulon C., et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011, 19(1):31-44.
98. Blank M., Shoenfeld Y. Histidine-rich glycoprotein modulation of immune/autoimmune, vascular, and coagulation systems. Clin Rev Allergy Immunol 2008, 34(3):307-312.
99. Reddy S.B., Williamson S.K. Tirapazamine: a novel agent targeting hypoxic tumor cells. Expert Opin Investig Drugs 2009, 18(1):77-87.
100. Aerts J.G., Amelink A., van der Leest C., Hegmans J.P., Hemmes A., den Hamer B., et al. HIF1a expression in bronchial biopsies correlates with tumor microvascular saturation determined using optical spectroscopy. Lung Cancer 2007, 57(3):317-321.
101. Yasuda H., Nakayama K., Watanabe M., Suzuki S., Fuji H., Okinaga S., et al. Nitroglycerin treatment may enhance chemosensitivity to docetaxel and carboplatin in patients with lung adenocarcinoma. Clin Cancer Res 2006, 12(22):6748-6757.
102. Yasuda H., Yamaya M., Nakayama K., Sasaki T., Ebihara S., Kanda A., et al. Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small-cell lung cancer. J Clin Oncol 2006, 24(4):688-694.
103. Goh J., Kirk E.A., Lee S.X., Ladiges W.C. Exercise, physical activity and breast cancer: the role of tumor-associated macrophages. Exerc Immunol Rev 2012, 18:158-176.
104. Heuvers M.E., Aerts J.G., Cornelissen R., Groen H., Hoogsteden H.C., Hegmans J.P. Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. BMC Cancer 2012, 12:580.